3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
6
Lymphoid
4
Gastrointestinal
4
Genitourinary
3
Other solid neoplasm
2
Thoracic
1
Plasma cell
1
Other
1
Myeloid
1
CNS
1
Breast
1
Conditions
Recurrence
1
Multiple Myeloma
1
Interventions
Dexamethasone
870
Lenalidomide
456
Bortezomib
454
Cyclophosphamide
365
Melphalan
271
Calcium Dobesilate
262
daratumumab
233
pomalidomide
207
carfilzomib
182
fludarabine phosphate
140
fludarabine
136
Thalidomide
125
Peripheral Blood Stem Cell Transplantation
119
Filgrastim
114
ixazomib
93
Mycophenolic Acid
90
Granulocyte Colony-Stimulating Factor
89
Whole-Body Irradiation
87
Busulfan
87
dexamethasone acetate
86
Tacrolimus
78
dexamethasone 21-phosphate
74
Cyclosporine
68
isatuximab
67
auricularum
67
Prednisone
65
elotuzumab
58
belantamab mafodotin
56
Antilymphocyte Serum
56
Etoposide
53
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Dosage Forms
×
Plasma cell
×
Clear all
NCT02939183
2024-09-26
INTREPID-1
Amgen
Phase 1
Completed
61 enrolled
28 charts